CRSP - Gene editing therapy companies rise on word of streamlined FDA approval process
2025-10-31 12:14:01 ET
More on CRISPR Therapeutics
- Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook
- Crispr: Investors Waiting Patiently For In-Vivo
- Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now Back On Track
- CRISPR Therapeutics files for $600M stock offering
- Cathie Wood's Ark Invest weekly recap: lifts stake in Bullish and Brera, trims Roku and Tempus AI